Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study
Authors
Andre, T.Falcone, A.
Shparyk, Y. V.
Moiseenko, F. V.
Polo, E.
Csoszi, T.
Bragagnoli, A. S. C.
Liposits, G.
Chmielowska, E.
Delaporte, F.
Hassan, H.
Skanji, D.
Amellal, N.
Saunders, Mark P
Affiliation
Hôpital Saint-Antoine, Paris, FranceIssue Date
2023
Metadata
Show full item recordCitation
Andre T, Falcone A, Shparyk YV, Moiseenko FV, Polo E, Csoszi T, et al. Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000717.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.3512Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3512Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.3512